Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 7 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Alpelisib and Olaparib for treating platinum-resistant or refractory BRCA wild-type ovarian cancer	Alpelisib (BYL719; Piqray) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Ovarian cancer	Female Reproductive Cancer	2022	View \| Download
AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy	Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Xevinapant (Debio 1143; AT-406)	Ovarian cancer	Female Reproductive Cancer	2018	View \| Download
Cediranib with olaparib for previously treated platinum resistant recurrent ovarian cancer	Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Ovarian cancer	Female Reproductive Cancer	2021	View \| Download
Durvalumab with bevacizumab and chemotherapy for treating advanced ovarian cancers	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Ovarian cancer	Female Reproductive Cancer	2023	View \| Download
Olaparib in combination with bevacizumab for ovarian, fallopian tube or primary peritoneal cancer – maintenance therapy	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Fallopian tube cancer , Ovarian cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Pembrolizumab with chemotherapy for platinum-resistant recurrent ovarian cancer after 1 or 2 therapies	Chemotherapy , Pembrolizumab (Keytruda; MK-3475)	Ovarian cancer	Female Reproductive Cancer	2023	View \| Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation	Melphalan hydrochloride (Cydex; CDX-353; Phelinun)	Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer	Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer	2021	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications